Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

By S. Baldacci, E.J. Brea, F. Facchinetti, Zhaorong Li, Kenneth Ngo, S. Malhotra, M. Booker, M. Tolstorukov, Sachiv Chakravarti, Conor Hinchey and 27 more. 2025

Subfields: Cancer Research, Oncology, Pharmacology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “Notably, TROP2-targeted CAR-T cell therapy has been shown to eradicate drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer, highlighting a potential role of TROP2 in tumor cell plasticity and therapy resistance (46).”